By Billy Candra 
A groundbreaking study led by Professor Sophia Karagiannis’s group at King’s College London has revealed the precise mechanisms by which a novel antibody therapy, derived from a previously overlooked class of antibodies, ignites the body’s own defenses against ovarian cancer. This research, published in the prestigious journal Nature Communications, not only deepens the scientific community’s understanding of patient responses to this innovative treatment but also paves the way for a new paradigm in cancer immunotherapy, particularly for solid tumours that have historically resisted conventional approaches.
Unlocking IgE’s Potential Against Ovarian Cancer
Immunotherapy, a rapidly evolving field in oncology, harnesses the immune system to identify and eliminate cancer cells. The vast majority of antibody treatments currently employed in cancer therapy are based on immunoglobulin G (IgG) antibodies. While IgG-based therapies have achieved remarkable successes against various cancers, their efficacy against ovarian cancer has remained limited, underscoring the urgent need for alternative strategies.
The King’s College London team stands at the forefront of pioneering a new class of antibody treatment, utilizing immunoglobulin E (IgE) antibodies. Unlike their IgG counterparts, IgE antibodies are more commonly associated with triggering allergic reactions and stimulating immune cells to combat parasitic infections. A key distinguishing feature of IgE antibodies is their exceptionally tight binding to immune cells predominantly found in tissues, rather than primarily activating circulating immune cells in the bloodstream, a characteristic of IgGs. This unique tissue-binding property led researchers to hypothesize that IgE could effectively engage immune cells directly within the tumour microenvironment, a critical battleground often characterized by immune suppression.
For over a decade, Professor Karagiannis and her team have been diligently working to harness these potent immune-boosting capabilities of IgE specifically against solid cancers, a category that includes ovarian cancer. This innovative approach represents a significant departure from established immunotherapeutic modalities and offers a novel avenue for therapeutic development.
From Bench to Bedside: Early Clinical Success with MOv18 IgE
The focal point of this research is an IgE antibody designated MOv18. The team initiated their investigations by exploring MOv18’s capacity to activate immune cells isolated from ovarian cancer patients and its broader influence on the intricate tumour environment. The findings from their initial studies were compelling, demonstrating that MOv18 IgE operates through a unique mechanism: it actively reverses the immune system’s suppression, a common tactic employed by tumours to evade detection and destruction, by activating distinct groups of immune cells to target the malignant cells.
The journey of MOv18 IgE has already seen promising results in a Phase Ia clinical trial. This trial, meticulously designed and executed by King’s researchers in collaboration with the National Institute for Health and Care Research (NIHR) Guy’s and St Thomas’ Clinical Research Facility and supported by Cancer Research UK’s Centre for Drug Development, provided the first human evidence of the antibody’s potential. In a landmark case, even at low doses, MOv18 IgE induced tumour shrinkage in a patient with ovarian cancer who had previously shown no response to conventional therapies. This early clinical success underscored the urgent need to understand the precise biological mechanisms underpinning MOv18 IgE’s action within the complex immune landscape of ovarian cancer. The current study, published in Nature Communications, was specifically designed to unravel this critical question.
Deciphering the Immune Mechanism: Macrophages and T-Cells
The multidisciplinary study, a collaborative effort involving King’s College London, Guy’s and St Thomas’ NHS Foundation Trust, the Medical University of Vienna, Fondazione IRCCS Instituto Nazionale dei Tumori in Milan, and SeromYx Systems, Inc., delved into the intricate interactions between MOv18 IgE and various immune cell populations in ovarian cancer patients. The primary focus was on macrophages, a type of immune cell traditionally known for its crucial role in fighting infections and eliminating microorganisms.
However, the researchers recognized that cancer often orchestrates a cunning manipulation of macrophages. Tumours can corrupt these essential immune cells, effectively suppressing their ability to mount an immune response and, even more insidiously, re-programming them to actively support tumour growth and progression. This phenomenon, where macrophages transition from anti-tumour agents to pro-tumour facilitators, represents a significant hurdle in effective cancer treatment.
Prior research, predominantly conducted in animal models, had hinted that MOv18 IgE possessed the ability to reactivate these corrupted macrophages, redirecting them from tumour support back towards a cancer-fighting role. To validate these observations within the human context of ovarian cancer, the research team adopted a two-pronged approach. Firstly, they collected macrophages from healthy donors and subsequently exposed these cells to cancerous fluid samples obtained from the peritoneal cavity—the primary site of ovarian cancer metastasis—of patients diagnosed with ovarian cancer. Secondly, and more directly, they isolated macrophages directly from these patient-derived cancerous fluid samples. All patient samples utilized in this critical phase of the research were collected ethically and meticulously from Guy’s and St Thomas’ NHS Foundation Trust.
In both experimental scenarios, the team consistently observed that the presence of ovarian cancer significantly suppressed the immune activity of macrophages. Crucially, their groundbreaking discovery revealed that MOv18 IgE could effectively bind to and activate these suppressed macrophages, empowering them to actively kill ovarian cancer cells. Furthermore, this activation by MOv18 IgE extended its beneficial effects beyond macrophages. It demonstrably reversed the immunosuppressive impact that ovarian cancer macrophages exerted on another vital group of immune cells: T cells. T cells are widely recognized for their indispensable role in orchestrating and maintaining robust, long-term immune responses against cancer in patients, making their activation a critical component of successful immunotherapy.
A Detailed Look at Cellular Reprogramming
Dr. Gabriel Osborn, who conducted this pivotal research during his PhD studies at King’s College London, elaborated on the intricate cellular dynamics observed. "We found that in patients, ovarian cancer effectively re-programmed macrophages away from their normal immune activation pathways. Instead, these re-programmed macrophages formed a complex immunosuppressive web, often in association with T cells, which could severely restrict the body’s anti-cancer immunity in patients," Dr. Osborn explained. "However, our findings showed that MOv18 IgE induced patient macrophages to not only kill cancer cells but also to undergo a highly inflammatory activation. This inflammatory state was critical, as it reversed their suppressive effects on T cells. This study adds profoundly important patient-level information, validating what we had previously observed for MOv18 IgE in laboratory settings, and reveals, for the first time, that IgE-driven macrophage stimulation possesses the capacity to activate the wider tumour immune system." This detailed understanding of MOv18 IgE’s mechanism provides a robust foundation for its continued development and application.
Validation in Patient Samples
Building upon their compelling in vitro and mechanistic laboratory findings, the research team sought to validate these observations directly within the context of human patients. They meticulously analyzed tumour biopsies from two patients who had participated in the Phase Ia clinical trial. For each patient, a biopsy was collected prior to the administration of MOv18 IgE treatment, serving as a baseline. A second biopsy was then collected after the patient had undergone treatment. The comparative analysis of these pre- and post-treatment samples yielded significant insights: a marked increase in the numbers of both macrophages and T cells was observed within the post-treatment samples. This in vivo evidence strongly indicated that these two critical groups of immune cells—macrophages and T cells—play a central and synergistic role in mediating the potent anti-tumour activity of MOv18 IgE, thereby validating the mechanistic findings from their laboratory investigations.
Expert Insights and Future Directions
Professor Sophia Karagiannis, Professor of Translational Cancer Immunology and Immunotherapy at King’s College London and the senior author of the study, emphasized the profound significance of these findings. "Understanding the biology of how a treatment works is not merely academic; it is absolutely essential for bringing effective treatments closer to patients," Professor Karagiannis stated. "Our research has unveiled that immune cells, which are typically inhibited and rendered ineffective within the hostile ‘microenvironment’ of the tumour, are effectively directed by IgE to specifically target the cancer cells. While we are making significant progress with clinical testing in patients, it remains imperative that we continue our relentless quest towards understanding precisely how MOv18 IgE, and indeed a wider panel of IgE-based antibodies that we are currently studying, harness the immune system across different groups of patients and various cancer types." Her vision underscores the long-term commitment to exploring the full therapeutic potential of IgE.
Dr. Debra Josephs, a consultant medical oncologist at Guy’s and St Thomas’ NHS Foundation Trust and a co-author of the study, played a crucial role in developing the pre-clinical research studies that guided MOv18 IgE towards clinical testing. She highlighted the broader mission: "Our unwavering focus is to deepen our understanding of the immune system and its intricate interaction with cancer, with the ultimate goal of discovering superior treatments for patients. During the preclinical development of MOv18 IgE, we demonstrated the critical role of activation and subsequent migration of tumour-associated macrophages into cancer lesions for this antibody treatment to be effective. This latest research marks an immensely important next step in the development of MOv18 IgE by significantly advancing our understanding of macrophage-mediated mechanisms, thereby robustly supporting the therapeutic potential of this novel antibody."
Professor James Spicer, Professor of Experimental Cancer Medicine at King’s College London, a consultant in medical oncology at Guy’s and St Thomas’ NHS Foundation Trust, and the Chief Clinical Investigator of the MOv18 IgE Phase Ia trial, also a co-author of the study, articulated the urgent clinical need. "We are relentlessly striving to achieve better outcomes for our patients. Clear and tangible progress is being made by thoroughly studying the immune system and the complex environment in which cancer grows," Professor Spicer observed. "In our ongoing research, we are striving to understand how we can most effectively capitalize on the unique power of IgE to develop novel, highly effective treatments, which will ultimately complement and enhance established IgG antibody drugs currently used in clinical practice." This perspective highlights the complementary rather than competitive role IgE therapies could play.
The Broader Landscape of Cancer Immunotherapy
The development of MOv18 IgE represents a significant advancement in the burgeoning field of immunotherapy. While IgG-based monoclonal antibodies have revolutionized the treatment of many cancers by blocking immune checkpoints or directly targeting cancer cells, their limitations in certain solid tumours, particularly those with highly immunosuppressive microenvironments like ovarian cancer, have been a persistent challenge. The unique properties of IgE—its strong tissue binding and potent activation of macrophages—offer a distinct advantage. This could potentially bypass some of the resistance mechanisms encountered by traditional immunotherapies, opening up new therapeutic avenues for patients who have exhausted other options. The implications extend beyond ovarian cancer, suggesting that IgE-based therapies could be tailored for other difficult-to-treat solid tumours where IgG antibodies have fallen short.
Addressing the Ovarian Cancer Challenge
Ovarian cancer remains one of the most lethal gynecological cancers, with a global incidence that underscores its public health significance. According to the World Cancer Research Fund International, ovarian cancer is the eighth most common cancer in women worldwide. A significant challenge in its management is the typically late diagnosis, often occurring when the disease has already spread beyond the ovaries, leading to lower survival rates. For instance, in the UK, only about 35% of women diagnosed with ovarian cancer survive for five years or more. Standard treatments, including surgery, chemotherapy, and sometimes targeted therapies, are often effective initially, but recurrence rates remain high. The development of new, effective treatments like MOv18 IgE is therefore not just an incremental step but a critical leap forward in improving patient outcomes and offering hope where current options are limited. The ability of MOv18 IgE to shrink tumours in patients unresponsive to conventional therapy highlights its potential to address this unmet clinical need directly.
The work received crucial financial and infrastructural support from several key organizations, including Cancer Research UK, the Medical Research Council, and Breast Cancer Now. Further acknowledgment was extended for support from the Cancer Research UK City of London Centre and the King’s Health Partners Centre for Translational Medicine, underscoring the collaborative and resource-intensive nature of such pioneering scientific endeavors. This collective effort highlights the commitment of the scientific and medical communities to push the boundaries of cancer treatment and bring novel therapies to patients in urgent need.